Vera Therapeutics grants inducement awards to 10 new employees
Vera Therapeutics granted inducement awards to 10 new employees on June 2, 2026, including stock options for 28,800 shares at $31.26 each and RSUs for 14,150 shares. The awards vest over four years and were approved under Nasdaq Listing Rule 5635(c)(4).
*this image is generated using AI for illustrative purposes only.
Vera Therapeutics, Inc. granted inducement awards to ten new employees on June 2, 2026, consisting of non-qualified stock options to purchase 28,800 shares of Class A common stock and restricted stock units (RSUs) underlying 14,150 shares of Class A common stock. The awards were approved by the Compensation Committee of the Board of Directors as an employment inducement under the Vera Therapeutics, Inc. 2024 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option granted on June 2, 2026, carries an exercise price of $31.26 per share, which equals the company's closing trading price on that date. The options will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the remainder vesting monthly over the subsequent 36 months, contingent on continued service.
The RSU awards will also vest over four years, with 25% of the underlying shares vesting on each anniversary of either May 20 or August 20, 2026, depending on the new employee's start date. All awards are subject to the terms of the Inducement Plan and the applicable award agreements.
Award Details
| Award Type | Shares Covered | Exercise Price | Vesting Schedule |
|---|---|---|---|
| Non-qualified stock options | 28,800 | $31.26 | 4 years (25% at 1 year, monthly thereafter) |
| Restricted stock units (RSUs) | 14,150 | N/A | 4 years (25% annually) |
The grants are intended as material inducements for the new employees to join the company. Vera Therapeutics focuses on developing treatments for serious immunological diseases, with its lead product candidate being atacicept.
Does the hiring of ten new employees indicate an expansion of clinical trials for lead candidate atacicept?
How will the dilution from these 42,950 new shares impact existing shareholders over the next four years?
Is the current stock price of $31.26 sustainable given the company's development stage and cash burn?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
